Daniel Egan

University of Washington Medical Center — United States

Medicine · Health Sciences

11h-index718citations42works9.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(12), Chronic Myeloid Leukemia Treatments(11), CAR-T cell therapy research(11), Acute Myeloid Leukemia Research(8), Hematopoietic Stem Cell Transplantation(5)

Publications42 total

A phase I/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: skewing towards NK-like phenotype impairs T cell function and persistence
Nature Communications·2025· 4 citedOpen Access
Efficacy and Safety with Extended Follow-up in a Phase 1 Study of BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Heavily Pretreated Relapsed/Refractory (RR) Multiple Myeloma (MM)
Blood·2024· 20 cited
Idecabtagene Vicleucel (Ide-cel) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Front-Line Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up
Blood·2024· 4 citedOpen Access
A Phase 1 Study of the Oral CDK9 Inhibitor Voruciclib in Relapsed/Refractory (R/R) B-Cell Lymphoma (NHL) or Acute Myeloid Leukemia (AML)
Blood·2023· 4 cited
Conditioning Impacts on Regulatory T-Cells (Tregs) in the Microenvironment of AML: Observations from the Phase 1 Cynk-001-AML-001 Trial
Blood·2023
Leukemia Blasts Induce NK-like Dysfunction in AML-Specific T Cells
Blood·2023Open Access
Results of Cynk-001-AML-001: A Phase I Multi-Dose Study Evaluating the Safety, Tolerability, and Persistence of Cynk-001 in Adults with De Novo or Secondary Acute Myeloid Leukemia in Morphologic Complete Remission with Minimal Residual Disease or Relapsed/Refractory AML
Blood·2023· 6 cited
Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Clinical High-Risk Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Frontline Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up
Blood·2023· 11 cited
BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study
Blood·2023· 55 cited
P-037 BMS-986393 (CC-95266), a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted CAR T-cell therapy for relapsed/refractory multiple myeloma (RRMM): results from a phase 1 study
Clinical Lymphoma Myeloma & Leukemia·2023
S193: BMS-986393 (CC-95266), A G PROTEIN–COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D (GPRC5D)–TARGETED CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1 STUDY
HemaSphere·2023· 15 citedOpen Access
P871: IDECABTAGENE VICLEUCEL (IDE-CEL) IN PATIENTS WITH AN INADEQUATE RESPONSE TO FRONTLINE AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT): RESULTS FROM KARMMA-2 COHORT 2C
HemaSphere·2023· 2 citedOpen Access
A randomized, open-label study of the efficacy and safety of galinpepimut-S (GPS) maintenance monotherapy compared to investigator's choice of best available therapy (BAT) in patients with acute myeloid leukemia (AML) who have achieved complete remission (CR) after second-line salvage therapy.
Journal of Clinical Oncology·2023· 1 cited
Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial
Blood·2022· 37 cited
The role of adjuvant chemotherapy in the management of acute promyelocytic leukemia differentiation syndrome
Frontiers in Oncology·2022· 3 citedOpen Access
Issue Information
AEM Education and Training·2022Open Access
Targeting an alternate Wilms’ tumor antigen 1 peptide bypasses immunoproteasome dependency
Science Translational Medicine·2022· 37 citedOpen Access
Initial Safety Results from a Phase II Study of Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Blood·2021
Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Blood·2020· 1 cited
The Efficacy of Passive Valve Antimicrobial Swab Caps Against Existing Clabsi Prevention Bundle in an Adult Hematology Inpatient Population: A Quality Improvement Initiative
Blood·2020
page 1 of 3Next →

Frequent Co-authors

Jerald P. Radich(10), Jesús G. Berdeja(8), Cecilia C.S. Yeung(7), Aude G. Chapuis(6), Merav Bar(6), Philip D. Greenberg(6), Thomas M. Schmitt(5), Kelly G. Paulson(5), Valentin Voillet(5), Daniel Hunter(5), Raya Mawad(5), Raphaël Gottardo(4), Felecia Wagener(4), Susan Bal(4), Omar Nadeem(4), Larry D. Anderson(4), Adriana Rossi(4), Luciano J. Costa(4), Hongxiang Hu(4), Safiyyah Ziyad(4)